Contrasting Edgewise Therapeutics (NASDAQ:EWTX) and Can-Fite BioPharma (NYSE:CANF)

Edgewise Therapeutics (NASDAQ:EWTX) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings and target prices for Edgewise Therapeutics and Can-Fite BioPharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	0	1	7	0	2.88
Can-Fite BioPharma	0	0	2	1	3.33

Edgewise Therapeutics presently has a consensus target price of $45.38, suggesting a potential upside of 125.41%. Can-Fite BioPharma has a consensus target price of $14.00, suggesting a potential upside of 900.00%. Given Can-Fite BioPharma’s stronger consensus rating and higher probable upside, analysts clearly believe Can-Fite BioPharma is more favorable than Edgewise Therapeutics.

Volatility & Risk

Edgewise Therapeutics has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500.

Insider and Institutional Ownership

21.0% of Can-Fite BioPharma shares are owned by institutional investors. 24.1% of Edgewise Therapeutics shares are owned by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Edgewise Therapeutics and Can-Fite BioPharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-26.83%	-25.67%
Can-Fite BioPharma	N/A	N/A	N/A

Valuation & Earnings

This table compares Edgewise Therapeutics and Can-Fite BioPharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$100.16 million	($1.45)	-13.88
Can-Fite BioPharma	$667,000.00	7.43	-$7.63 million	($1.79)	-0.78

Can-Fite BioPharma has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks.

Summary

Can-Fite BioPharma beats Edgewise Therapeutics on 10 of the 13 factors compared between the two stocks.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.